

The InnoVal^{HC} Discussion Paper Series (2005–2023)

Discussion / Technical / Working Paper



Michael Schlander
in cooperation with Ramon Schaefer

The InnoVal^{HC} Discussion Paper Series
(2005–2023)

Discussion / Technical / Working Paper

Discussion Paper Series

**THE INNOVAL^{HC} DISCUSSION PAPER SERIES
(2005 – 2023)**

**DISCUSSION / TECHNICAL / WORKING PAPER
[SHORTLIST]**

Michael Schlander
in cooperation with Ramon Schaefer

Wiesbaden, January 2024
INNOVAL^{HC}



About the Authors

Michael Schlander^{a-d}

in cooperation with Ramon Schaefer^{a-c}

^aInstitute for Innovation & Valuation in Health Care,
Aschaffenburg and Wiesbaden, Germany;

^bDivision of Health Economics at German Cancer Research Center
(Deutsches Krebsforschungszentrum, DKFZ), Heidelberg, Germany;

^cUniversity of Heidelberg, Mannheim Medical Faculty,
Mannheim, Germany;

^dUniversity of Heidelberg, Alfred Weber Institute,
Heidelberg, Germany;

Correspondence:

Professor Michael Schlander, M.D., Ph.D., M.B.A.

Institute for Innovation & Valuation in Health Care (InnoVal^{HC})

An der Ringkirche 4, D-65197 Wiesbaden / Germany

Phone: +49 (0) 611 4080 789 12; Facsimile: +49 (0) 611 4080 789 99

E-Mail: michael.schlander@innoval-hc.com

Discussion papers can be downloaded via the [Institute's website](#), or they are available on request => please contact: info@innoval-hc.com.



- ↪ R. Schaefer, M. Schlander:
The Heidelberg Health Economics Summer [& Winter]
Schools 2006-2023: History, International Evaluation (2023)
& Outlook.
InnoVal^{HC} Discussion Paper No. 36 / 2023
(ISBN 978 3 941609 34 1).
- ↪ M. Schlander, H. Telsler, B. Fischer, T. von Rechenberg, D.
Hernandez, R. Schaefer – on behalf of the ESPM Project
Group:
The Swiss Social Preferences for Health Care Interventions
("SoPHI") Study – Briefing on Essential Study Insights &
Policy Implications.
InnoVal^{HC} Discussion Paper No. 35 / 2021
(ISBN 978 3 941609 33 4).
- ↪ M. Schlander, R. Schaefer, O. Schwarz:
The Economic Value of a Statistical Life Year in Europe:
Report of a Systematic Review [German].
InnoVal^{HC} Discussion Paper No. 34 / 2017
(ISBN 978 3 941609 32 7).
- ↪ M. Schlander:
Pharmaceutical Benefits Advisory Committee (PBAC)
Guidelines Review 2016: An International Perspective
[Expert Statement].
InnoVal^{HC} Discussion Paper No. 33 / 2016
(available on request).
- ↪ M. Schlander, K. Stenner, A. Gandjour:
Budgetary Impact and Cost Drivers of Drugs for Ultra-Rare
Diseases (URDs) in Europe.
InnoVal^{HC} Discussion Paper No. 32 / 2015
(ISBN 978 3 941609 31 0).



- ↪ M. Schlander, S. Holm, E. Nord, J. Richardson, S. Garattini, P. Kolominsky-Rabas, D. Marshall, U. Persson, M. Postma, S. Simoens, O. de Solà Morales, K. Tolley, M. Toumi:
Towards Social Cost Value Analysis: The Need for New Approaches for Evaluating Drugs for Ultra-Rare Diseases (URDs).
InnoVal^{HC} Discussion Paper No. 31 / 2015
(ISBN 978 3 941609 30 3).
- ↪ M. Schlander, C.C. Adarkwah, A. Gandjour:
Budget Impact of Drugs for Ultra-Rare Non-Oncological Diseases Projected to Remain Moderate in Europe.
InnoVal^{HC} Discussion Paper No. 30 / 2014
(ISBN 978 3 941609 29 7).
- ↪ M. Schlander, S. Garattini, S. Holm, P. Kolominsky-Rabas, E. Nord, U. Persson, M. Postma, J. Richardson, S. Simoens, O. de Solà Morales, K. Tolley, M. Toumi:
Beyond Incremental Cost per Quality-Adjusted Life Year (QALY) Ratios: The Need for Alternative Methods to Evaluate Medical Interventions for Ultra-Rare Disorders.
InnoVal^{HC} Discussion Paper No. 29 / 2013
(ISBN 978 3 941609 28 0).
- ↪ A. Gandjour, A. Gafni, M. Schlander:
Determining the Price for Pharmaceuticals in Germany: Comparing a shortcut for IQWiG's efficiency frontier method with the price set by the manufacturer for ticagrelor.
InnoVal^{HC} Discussion Paper No. 28 / 2013
(ISBN 978 3 941609 27 3).
- ↪ M. Schlander, S. Garattini, P. Kolominsky-Rabas, E. Nord, U. Persson, M. Postma, J. Richardson, S. Simoens, O. de Solà Morales, K. Tolley, M. Toumi:



Consensus Statement: “Determining the Value of Medical Technologies to Treat Ultra-Rare Disorders (URDs)”.

InnoVal^{HC} Discussion Paper No. 27 / 2013

(ISBN 978 3 941609 26 6).

- M. Schlander, H. Sandmeier, C. Affolter, C. Bosshard, T. Cueni, P. Gyger, A. Hebborn, K. Huber, E. Kraft, P. Strupler, P. Suter:
Schweizer HTA-Konsensus, Umsetzungspapier 6/2012:
Wirtschaftlichkeitsbewertung.
Basel, Bern, Solothurn and Wiesbaden, February 04, 2013.
InnoVal^{HC} Discussion Paper No. 26 / 2013
(ISBN 978 3 941609 25 9).
See also: www.swisshta.ch
- M. Schlander, H. Sandmeier, C. Affolter, C. Bosshard, T. Cueni, P. Gyger, A. Hebborn, K. Huber, E. Kraft, P. Strupler, P. Suter:
Schweizer HTA-Konsensus, Umsetzungspapier 5/2012:
Nutzenbewertung.
Basel, Bern, Solothurn and Wiesbaden, February 04, 2013.
InnoVal^{HC} Discussion Paper No. 25 / 2013
(ISBN 978 3 941609 24 2)
See also: www.swisshta.ch
- M. Schlander, H. Sandmeier, C. Affolter, C. Bosshard, T. Cueni, P. Gyger, A. Hebborn, K. Huber, E. Kraft, P. Strupler, P. Suter:
Schweizer HTA-Konsensus, Umsetzungspapier 4/2012:
Konkretisierung der WZW-Kriterien.
Basel, Bern, Solothurn and Wiesbaden, February 04, 2013.
InnoVal^{HC} Discussion Paper No. 24 / 2013
(ISBN 978 3 941609 23 5)
See also: www.swisshta.ch



- ↪ M. Schlander, H. Sandmeier, C. Affolter, C. Bosshard, T. Cueni, A. Faller, P. Gyger, A. Hebborn, K. Huber, E. Kraft, P. Suter:
Schweizer HTA-Konsensus, Umsetzungspapier 3/2012:
Complete (c-) HTAs.
Basel, Bern, Solothurn and Wiesbaden, November 13, 2012.
InnoVal^{HC} Discussion Paper No. 23 / 2012
(ISBN 978 3 941609 22 8).
See also: www.swisshta.ch
- ↪ M. Schlander, H. Sandmeier, C. Affolter, C. Bosshard, T. Cueni, A. Faller, P. Gyger, A. Hebborn, K. Huber, E. Kraft, P. Suter:
Schweizer HTA-Konsensus, Umsetzungspapier 2/2012:
Rapid (r-)HTAs.
Basel, Bern, Solothurn and Wiesbaden, November 13, 2012.
InnoVal^{HC} Discussion Paper No. 22 / 2012
(ISBN 978 3 941609 21 1).
See also: www.swisshta.ch
- ↪ C. Affolter, H. Sandmeier, M. Schlander, C. Bosshard, T. Cueni, A. Faller, P. Gyger, A. Hebborn, K. Huber, E. Kraft, P. Suter:
Schweizer HTA-Konsensus, Umsetzungspapier 1/2012:
Institutionelles.
Basel, Bern, Solothurn and Wiesbaden, November 13, 2012.
InnoVal^{HC} Discussion Paper No. 21 / 2012
(ISBN 978 3 941609 20 4).
See also: www.swisshta.ch
- ↪ M. Schlander, C. Affolter, H. Sandmeier, U. Brügger, C. Cao, T. Cueni, E. Kraft, G. de Pouvourville, A. Faller, P. Gyger, A. Hebborn, D. Herren, S. Kaufmann, R. Leu, P. Suter:
Schweizer HTA-Konsensus-Projekt: Leitsätze.



Basel, Bern, Solothurn and Wiesbaden, May 14, 2012.

InnoVal^{HC} Discussion Paper No. 20 / 2012

(ISBN 978 3 941609 19 8).

See also: www.swisshta.ch

- M. Schlander, C. Affolter, H. Sandmeier, U. Brügger, C. Cao, T. Cueni, E. Kraft, G. de Pouvourville, A. Faller, P. Gyger, A. Hebborn, D. Herren, S. Kaufmann, R. Leu, P. Suter:

Swiss HTA Consensus: Guiding Principles.

Basel, Bern, Solothurn and Wiesbaden, March 13, 2012.

InnoVal^{HC} Discussion Paper No. 19 / 2012

(ISBN 978 3 941609 18 1).

See also: www.swisshta.ch

- M. Schlander, C. Affolter, H. Sandmeier, U. Brügger, C. Cao, T. Cueni, G. de Pouvourville, A. Faller, P. Gyger, A. Hebborn, D. Herren, S. Kaufmann, R. Leu, P. Suter:

Swiss HTA Consensus Project: Cornerstones for Further Development in Switzerland.

Basel, Bern, Solothurn and Wiesbaden, October 19, 2011.

InnoVal^{HC} Discussion Paper No. 18 / 2011

(ISBN 978 3 941609 17 4).

See also: www.swisshta.ch

- M. Schlander, C. Affolter, H. Sandmeier, U. Brügger, C. Cao, T. Cueni, G. de Pouvourville, A. Faller, P. Gyger, A. Hebborn, D. Herren, S. Kaufmann, R. Leu, P. Suter:

Schweizer HTA-Konsensus-Projekt: Eckpunkte für die Weiterentwicklung in der Schweiz. (Health Technology Assessment (HTA): Systematische Bewertung medizinischer Interventionen in der sozialen Krankenversicherung.)

Basel, Bern, Solothurn and Wiesbaden, October 19, 2011.

InnoVal^{HC} Discussion Paper No. 17 / 2011



(ISBN 978 3 941609 16 7).

See also: www.swisshta.ch

- ↪ M. Schlander, C. Affolter, H. Sandmeier, U. Brügger, C. Cao, T. Cueni, G. de Pouvourville, A. Faller, P. Gyger, A. Hebborn, D. Herren, S. Kaufmann, R. Leu, P. Suter: Schweizer HTA-Konsensus-Projekt: Eckpunkte für die Weiterentwicklung in der Schweiz. (Health Technology Assessment (HTA): Systematische Bewertung medizinischer Interventionen in der sozialen Krankenversicherung.) Anhang. Basel, Bern, Solothurn and Wiesbaden, October 19, 2011. InnoVal^{HC} Discussion Paper No. 16 / 2011 (ISBN 978 3 941609 15 0). See also: www.swisshta.ch
- ↪ M. Schlander, C. Affolter, H. Sandmeier, U. Brügger, C. Cao, T. Cueni, G. de Pouvourville, A. Faller, P. Gyger, A. Hebborn, D. Herren, S. Kaufmann, R. Leu, P. Suter: Value and Valuation of Health Technologies: Bewertung medizinischer Interventionen in der sozialen Krankenversicherung. Dokumentation zum Thesenpapier (Eckpunkte des Schweizer HTA-Konsensus). Basel, Bern, Solothurn and Wiesbaden, October 19, 2011. InnoVal^{HC} Discussion Paper No. 15 / 2011 (ISBN 978 3 941609 14 3). See also: www.swisshta.ch
- ↪ M. Schlander: DIMDI HTA-Bericht Nr. 108: „Medikamentöse Therapie der ADHS im Erwachsenenalter in Deutschland“ - Validität der Schlussfolgerungen, Methodik und Aussagekraft. InnoVal^{HC} Discussion Paper No. 14 / 2010 (ISBN 978 3 941609 13 6).



- ↪ M. Schlander:
Sponsorship Bias in Health Economic Evaluations of Child
Psychiatric Drug Treatment.
InnoVal^{HC} Discussion Paper No. 13 / 2010
(ISBN 978 3 941609 12 9).
- ↪ M. Schlander:
Rational Treatment Choices in Attention-
Deficit/Hyperactivity Disorder:
The Contribution of Health Economics.
InnoVal^{HC} Discussion Paper No. 12 / 2010
(ISBN 978 3 941609 11 2).
- ↪ M. Schlander, G.-E. Trott, O. Schwarz:
Estimating the cost of attention-deficit/hyperactivity
disorder (ADHD) in Germany.
[Available in German: Wie teuer sind
Aufmerksamkeitsdefizit-/ Hyperaktivitätsstörungen für die
Gesetzliche Krankenversicherung in Deutschland?]
InnoVal^{HC} Discussion Paper No. 11 / 2009
(ISBN 978 3 941609 10 5).
- ↪ M. Schlander, J. Meyer:
Comparative Evaluation of Medical Technologies.
InnoVal^{HC} Discussion Paper No. 10 / 2009
(ISBN 978 3 941609 09 9).
- ↪ M. Schlander:
Comparative Effectiveness Programs: A Global Perspective,
Discussing Germany and the United Kingdom.
Briefing Document for The Galen Institute, Washington, DC.
InnoVal^{HC} Discussion Paper No. 09 / March 2009
(ISBN 978 3 941609 08 2).



- ↪ M. Schlander, O. Schwarz, A. Rothenberger, V. Roessner:
Tic disorders: prevalence and co-occurrence with attention-deficit/hyperactivity disorder in a German community sample.
InnoVal^{HC} Discussion Paper No. 08 / January 2009
(ISBN 978 3 941609 07 5).
- ↪ M. Schlander:
In Search of Efficiency.
[Available in German: Der Effizienz auf der Spur]
InnoVal^{HC} Discussion Paper No. 07 / July 2008
(ISBN 978 3 941609 06 8).
- ↪ M. Schlander:
House of Commons Health Committee Inquiry into aspects of the work of the National Institute for Health and Clinical Excellence.
InnoVal^{HC} Discussion Paper No. 06 / May 2007
(ISBN 978 3 941609 05 1).
- ↪ C. Thielscher, M. Schlander:
How Much Glasnost for German Health Care?.
[Available in German: Wieviel Glasnost braucht das deutsche Gesundheitswesen?]
InnoVal^{HC} Discussion Paper No. 05 / January 2007
(ISBN 978 3 941609 04 4).
- ↪ M. Schlander:
That Infamous Fourth Hurdle: Ten Things to Consider When Regulating Reimbursement of New Drugs in Germany.
[Available in German: Rationaler Umgang mit neuen Medikamenten: Zehn Thesen zur geplanten „Vierten Hürde“ für neue Arzneimittel.]



InnoVal^{HC} Discussion Paper No. 04 / November 2006

[2nd edition]

(ISBN 978 3 941609 03 7).

→ M. Schlander:

Long-Acting Medications for the Hyperkinetic Disorders.

InnoVal^{HC} Discussion Paper No. 03 / September 2006

(ISBN 978 3 941609 02 0).

→ M. Schlander:

Impact of Attention-Deficit/Hyperactivity Disorder (ADHD)
on Prescription Drug Spending for Children and
Adolescents: Increasing Relevance of Health Economic
Evidence.

InnoVal^{HC} Discussion Paper No. 02 / June 2006

(ISBN 978 3 941609 01 3).

→ M. Schlander, C. Thielscher, O. Schwarz:

Affordable Health Care Expenditure and Real Economic
Growth.

InnoVal^{HC} Discussion Paper No. 01 / July 2005

(ISBN 978 3 941609 00 6).



© INNOVAL^{HC} • Wiesbaden 2024

Discussion Paper Series Editors:
Michael Schlander and Oliver Schwarz

INNOVAL^{HC}
Institute for Innovation & Valuation in Health Care
Institut für Innovation & Evaluation im Gesundheitswesen e.V.

Prof. Dr. Michael Schlander (Chairman)
Prof. Dr. Oliver Schwarz (Vice Chairman)
Prof. Dr. G.-Erik Trott (Vice Chairman)

Official Site: Luitpoldstraße 2-4 • D-63739 Aschaffenburg
Registered at Vereinsregister Aschaffenburg VR 1371

Recognized as a not-for-profit organization by
(als gemeinnützig anerkannt vom) Finanzamt Aschaffenburg

Office Address: An der Ringkirche 4 • D-65197 Wiesbaden (Germany)

www.innoval-hc.com

